Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Ratio (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Equity Ratio readings, the most recent being 0.34 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 33.31% year-over-year to 0.34, compared with a TTM value of 0.34 through Dec 2025, up 33.31%, and an annual FY2025 reading of 0.34, up 33.31% over the prior year.
  • Equity Ratio hit 0.34 in Q4 2025 for Apellis Pharmaceuticals, down from 0.38 in the prior quarter.
  • The five-year high for Equity Ratio was 0.42 in Q1 2023, with the low at 0.2 in Q2 2021.
  • Median Equity Ratio over the past 5 years was 0.27 (2023), compared with a mean of 0.24.
  • The sharpest move saw Equity Ratio tumbled 179.16% in 2021, then skyrocketed 532.63% in 2022.
  • Year by year, Equity Ratio stood at 0.23 in 2021, then decreased by 0.82% to 0.22 in 2022, then increased by 10.37% to 0.25 in 2023, then grew by 4.7% to 0.26 in 2024, then surged by 33.31% to 0.34 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.34, 0.38, and 0.19 for Q4 2025, Q3 2025, and Q2 2025 respectively.